Chronos Archive seal

Review checklist: Frédéric Chopin (HR-NI020)

All records · Back to the record · Dossier (sources.md) · Terminology · Report a problem · Comments

Everything a reviewer needs to judge, gathered from the record. Release status: draft.

Review status

ReviewStatusReviewerDateNotes
schema validationnot_startedRun scripts/build.ps1 -Conformance.
clinical reviewnot_startedAwaiting clinician review.
provenance reviewnot_startedBiography from the Fryderyk Chopin Institute, the Polish Music Information Centre, and the Valldemossa museum page; retrospective diagnoses from PubMed records. The birth-date conflict (March 1 or February 22, 1810) is recorded. Tuberculosis is graded D as diagnosed in his lifetime and R (probable) for the 2014 heart examination; cystic fibrosis, alpha-1 antitrypsin deficiency, and heart failure are R and disputed.
safe messaging reviewnot_startedThe two claims about low mood are marked sensitive and quoted in the source's lay words, not as diagnoses. PHQ-9 at most 7 and no F-code, so no safety assessment is required; item 9 is recorded at each PHQ-9. George Sand appears only in documented history claims; contacts in the investigation are synthetic and unnamed, and no result is attributed to anyone.

Judgment calls (dossier editorial resolutions)

  1. Name. The display name is Frédéric Chopin. The roster spells it “Frederick Chopin”; the French form he used in Paris is preferred. The aliases are the Polish forms, Fryderyk Chopin and Fryderyk Franciszek Chopin, which appear in no other record. The name splits simply into a given name and a family name, so identity.name_parts is not needed.
  2. Birth date. March 1, 1810, the date he and his family used and the Institute gives, is preferred; February 22, 1810, from the baptismal certificate written several weeks after the birth, is recorded as a conflicting alternative.
  3. Index age and dates. Synthetic date of birth March 1, 1998; shift 188 years. The index visit on March 17, 2026 (age 28) maps to March 17, 1838. The chronic-care visits on March 20, April 7, May 15, and July 21, 2026, the sick visit on June 9, 2026, and the preventive visit on September 15, 2026 map to the same days of 1838, when he lived and taught in Paris; he left for Majorca at the end of October 1838, after the last visit. The episode is set in the year before the Majorca crisis and ends in cure; that is a synthetic outcome of modern treatment and does not contradict the documented course in the true frame.
  4. Presenting problem. The cough with hemoptysis and weight loss is its own problem (PRB-001, R04.2), resolved at the results visit, when pulmonary tuberculosis (PRB-002, A15.0) is recorded. The intake documents show only the suspicion, the samples, and the plan, with no results or regimen.
  5. Choice of diagnosis. Pulmonary tuberculosis was chosen as the one modern diagnosis because it is the diagnosis made in his lifetime (graded D: the Majorca symptoms of tuberculosis and the 1849 diagnosis after two hemorrhages), the cause of death the Institute gives, and the conclusion of the 2014 examination of his heart (graded R, probable: a fibrinous pericarditis with nodules interpreted as tuberculous, judged the probable immediate cause of death). Cystic fibrosis (proposed in 2003), alpha-1 antitrypsin deficiency (proposed in 2003), and dilated cardiomyopathy with heart failure and cirrhosis (proposed in 2018) are R and disputed and stay off the problem list. In the modern frame the genetic alternatives are tested honestly (sweat chloride 18 mmol/L, alpha-1 antitrypsin 142 mg/dL, and no bronchiectasis or emphysema on CT), all synthetic, and found absent. The brief described the heart examination as taking place in 2017; the sources show it was examined in 2014 and the Am J Med letter was published online in October 2017, so 2014 is recorded.
  6. Regimen. He is eligible for the four-month rifapentine-moxifloxacin regimen under the 2022 CDC interim guidance (weight 48.4 kg, at least 40 kg; pulmonary only; HIV negative; no QT history or interacting drugs; normal potassium, magnesium, liver tests, and creatinine), and he chose it because it returns him to full work sooner. Pyrazinamide 1000 mg follows the 40 to under 55 kg band. The 2016 ATS/CDC/IDSA guideline is followed for diagnosis, infection control, and monitoring; the CDC guidance does not call for routine electrocardiograms, and none was done. The 2016 guideline was issued by ATS, CDC, and IDSA (and endorsed by ERS), not by all four; the 2025 update is the ATS/CDC/ERS/IDSA document.
  7. Microbiology and qualitative tests. Smears, the amplification test, molecular resistance tests, cultures, phenotypic susceptibility, the interferon-gamma release assay, HIV, and hepatitis serology are recorded in the note text and monitoring tables, because the canonical schema carries only numeric results. All are synthetic.
  8. Real people. George Sand appears only in documented history claims (CLM-0008, CLM-0012); the fiancée's family appears only in the documented 1836 claim, unnamed. His sister's death of tuberculosis in 1827 appears only in the family history and the historical basis. No relative or companion appears in the visit notes, and no decision, statement, or health fact is attributed to any real person in the modern episode. His contacts (students, friends) are synthetic and unnamed, and none of their results is part of his record.
  9. Mental health. The documented “doubt and depression” on Majorca and the effect of the 1847 parting are marked sensitive and kept in the source's lay words; they are after the index date and not shown in intake documents. The modern PHQ-9 scores (7, 4, 3) are synthetic and mild; no depression diagnosis is made, and no safety assessment is required (no F-code, PHQ-9 below 10). Item 9 is recorded as 0 each time.
  10. Stigma. His fear of being shunned (HC-003) echoes the documented fear of his illness on Majorca; the modern episode answers it with information, a timed return to teaching, and a contact investigation run by the health department.
  11. Synthetic content. All laboratory values, imaging, weights (height 170 cm is synthetic), the dosing history, the household and contacts, the dietitian care, the cold, and the preventive care are synthetic.
  12. Focused visits. The four chronic-care follow-ups (the results visit at three days with the consultation, two and a half weeks, the end of the intensive phase, and the end of treatment) are focused visits with protocol monitoring tables built from the 2022 CDC interim guidance and the ATS/CDC/IDSA guideline (symptoms, weight and pyrazinamide band, adverse effects including tendons and nerves, liver tests, electrolytes, ECG not indicated, sputum smear and culture, amplification test, molecular and phenotypic susceptibility, the two-month culture, IGRA, HIV and hepatitis serology, chest X-ray, observed doses and the completion windows, interactions, isolation, reporting, contact investigation, infectious diseases review), the CF Foundation and ATS/ERS standards (sweat chloride and alpha-1 antitrypsin), the malnutrition consensus, and the PHQ-9. One protocol deviation is recorded instead of an invented result: no monthly clinic review took place in the six weeks between the sick visit and the end of treatment; the nurse reviewed symptoms and side effects on every video call and the end-of-treatment findings were normal, so no harm is evident, and monthly reviews are now booked at the start.
  13. Sick and preventive visits. The sick visit is a cold in week 12, chosen to teach how to tell a viral infection from treatment failure, to avoid antibiotics, and to keep zinc and mineral remedies away from moxifloxacin and QT-prolonging drugs such as azithromycin away from it. The preventive visit is the adult preventive service at 28, with influenza vaccine and the screening done at the diagnosis carried forward; no tuberculosis test is repeated. Advance care planning is a brief discussion with no agent named.
  14. Consultation. The infectious diseases referral and the consultation by Ewa Kowalczyk-Grant, MD (a fictional consultant), on the day of the results visit, are S. She confirms the diagnosis, sets out his eligibility for the four-month regimen and the doses, the liver, tendon, and nerve monitoring, the release and return-to-teaching criteria, and the tests for cystic fibrosis and alpha-1 antitrypsin deficiency, and plans message reviews at two months and at the end. The record follows these recommendations, apart from the clinic-review gap recorded as a deviation.
  15. Not used. His later life after 1838, the works composed while ill, and the roster's “depression” and “extreme physical frailty” labels are not used as diagnoses. The letters to Nature and Am J Med that comment on the heart examination were not fetched beyond their bibliographic records and are not cited. Wikipedia and other secondary pages found in searches were not used.

Protocol deviations

Checks the monitoring protocol called for that the schedule did not perform. Each is recorded with its outcome and corrective action, never filled with an invented result.

VisitMeasureIntervalWhat happened
2026-07-21
Progress note 06 (C-CDA)
Clinical review (adherence, symptoms, adverse effects, weight)At least monthly during treatmentNo clinic review between the sick visit in early June and today, about six weeks, because the schedule went from the end of the intensive phase to the end of treatment. The nurse reviewed symptoms and side effects on every video call, and today's examination, weight, and tests are normal, so no harm is evident. Corrective action: monthly clinic reviews booked at the start of treatment for every patient on the four-month regimen

Orders and referrals without results in the record

VisitTypeItemStatusDetail
2026-03-20
Progress note 02 (C-CDA)
LaboratoryRapid molecular testing for isoniazid and fluoroquinolone resistanceOrderedSent on the first sample; pending
2026-03-20
Progress note 02 (C-CDA)
LaboratoryPhenotypic susceptibility (rifampin, isoniazid, pyrazinamide, moxifloxacin)OrderedOn the culture isolate when it grows
2026-03-20
Progress note 02 (C-CDA)
ReferralContact investigation (students, friends, close contacts)ReferredHealth department listing his students and other close contacts; their results are not part of his record
2026-03-20
Progress note 02 (C-CDA)
Self-managementNutrition: dietitian, intake, supplement drinksOrderedFirst dietitian visit by video this week
2026-03-20
Progress note 02 (C-CDA)
LaboratorySweat chloride and serum alpha-1 antitrypsinOrderedAdvised by infectious diseases; at the next visit, once he is out of isolation
2026-04-07
Progress note 03 (C-CDA)
LaboratoryPhenotypic susceptibility (rifampin, isoniazid, pyrazinamide, moxifloxacin)OrderedSet up on the baseline isolate; pending
2026-04-07
Progress note 03 (C-CDA)
ReferralContact investigation (students, friends, close contacts)ReferredIn progress with the health department; no results in his record
2026-05-15
Progress note 04 (C-CDA)
ReferralContact investigation (students, friends, close contacts)ReferredContinuing with the health department; no results in his record

Evidence to check

Retrospective claims (R)

ClaimStatementCertainty
CLM-0016A macroscopic examination of his preserved heart in 2014 found it enlarged and covered with a fibrinous coating with multiple small nodular foci, which the examiners interpreted as tuberculous pericarditis; they concluded that chronic tuberculosis was the most plausible diagnosis and that rapidly progressing tuberculous pericarditis was probably the immediate cause of death. An earlier review of his case history also judged tuberculosis the most probable diagnosis.probable
CLM-0017Cystic fibrosis has been proposed as the cause of his lifelong illness and death; the roster lists a "probable cystic fibrosis variant." The heart examination's authors later argued that the disease was infectious, not genetic.disputed
CLM-0018Alpha-1 antitrypsin deficiency has also been proposed, while noting that the lost autopsy record makes any diagnosis hard to confirm.disputed
CLM-0019Another documentary review proposed that he had dilated cardiomyopathy with heart failure and cirrhosis, rather than tuberculosis, as the cause of death.disputed

Sensitive claims

ClaimGradeStatement
CLM-0010DOn Majorca he suffered long periods of doubt and depression, associated with his illness, and the hostility of local people who feared his illness worsened his state of mind.
CLM-0012DThe final parting from George Sand in July 1847 and the loss of Nohant had a devastating effect on his mental and physical state, and he almost gave up composing.

Diagnoses not confirmed

None.

Notes to read

Every note in the record, with its type. All clinical content is synthetic.

Abnormal results

DateResultValueFlag
2026-03-17Hemoglobin12.1 g/dL (low)Low
2026-03-17Platelets442 10*3/uL (high)High
2026-03-17Albumin3.2 g/dL (low)Low
2026-05-15Hemoglobin13 g/dL (low)Low